▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1439 by analyst upside · 2026-08-12
DNLI
Denali Therapeutics Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+43.5%
implied upside to consensus target
Current Price $24.69
Consensus Target $35.44
Bull Target $42.0
Bear Target $27.0
Analysts Covering 16
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
14
Hold
1
Sell
0
52-Week Low $12.58
52-Week High $27.3
YTD Return +51.8%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.84
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $4M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $12.58
52-Week High $27.3
Current Price $24.69
Bear Target $27.0
Bull Target $42.0
● Now $24.69 ● Target $35.44
TRADING DATA
Avg Volume 1.8M
YTD Return +51.8%
Analyst Count 16
Consensus Buy
Upside to Target +43.5%
Last Updated 2026-08-12

ANALYST SUMMARY

Denali Therapeutics Inc. (DNLI) is currently trading at $24.69 with a Wall Street consensus price target of $35.44, implying potential upside of 43.5% over the next 12 months. 16 analysts currently cover DNLI, with a consensus rating of Buy - 94% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $42.0, while the most cautious has a target of $27.0.

DNLI operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 51.8% year-to-date and is currently trading near the upper end of its 52-week range of $12.58 – $27.3.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INDV +27.5%
Indivior Pharmaceuticals, Inc.
$5B · P/E 13.8x · Buy
GRFS +36.0%
Grifols, S.A.
$5B · P/E 10.5x · Buy
OPCH +18.7%
Option Care Health, Inc.
$4B · P/E 18.2x · Buy
CON +16.9%
Concentra Group Holdings Parent, Inc.
$4B · P/E 21.3x · Buy
ACAD +13.9%
ACADIA Pharmaceuticals Inc.
$5B · P/E 13.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for DNLI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-26 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-14 Building track record
BTIG reit
Buy → Buy 2026-05-11 38% win rate (8 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-05-08 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-04-22 29% win rate (7 calls)
Baird - Reiterated
Outperform → Outperform 2026-04-07 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-03-26 Building track record
Goldman Sachs - Reiterated
Buy → Buy 2026-03-26 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
62
out of 100
Coverage depth
22/30
Consensus clarity
18/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →